Skip to search formSkip to main contentSkip to account menu

axitinib

Known as: N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide, axitinibum 
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and… 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (2)

AG 013736Inlyta

Broader (3)

ImidazolesIndazolesProtein Kinase Inhibitors
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionReceptor Tyrosine Kinase Inhibitors [MoA]axitinib 1 MG Oral Tablet [Inlyta]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
This is a repository copy of A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
BACKGROUND: Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth… 
2016
2016
Development and Validation of a Superior High Performance Liquid Chromatographic Method for Quantification of Axitinib in Solid Oral Dosage Form
A stability-indicating reversed phase high performance liquid chromatographic method was developed to quantify axitinib (AXT) in… 
Review
2016
Review
2016
Axitinib treatment among patients with mRCC in a U.S. community oncology setting: A retrospective study of 135 patients.
569 Background: We have previously reported differences in a variety of outcome measures between clinical trial and real world… 
2016
2016
Powles, T. et al. (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer
BACKGROUND: Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth… 
2016
2016
Axitinib v léčbě metastatického renálního karcinomu
Cil: Vlastni retrospektivni zhodnoceni ucinnosti a tolerance axitinibu. Pacienti a metody: Celkem jsme hodnotili 11 pacientů s… 
2015
2015
The non-specific binding of tyrosine kinase inhibitors to human liver microsomes
240 words Introduction: 421 words Results and Discussion: 1795 words Abbreviations: CMC, critical micelle concentration; HLM… 
2013
2013
Angiogenesis and Lung Cancer
Tumors acquire blood vessels by co-option of neighboring vessels from sprouting or intus‐ suscepted microvascular growth and by… 
2010
2010
Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI.
3050 Background: Proliferation rebound during VEGFR TKI withdrawal has been reported. Pharmacodynamic (PD) study of this… 
Review
2009
Review
2009
Systemtherapie des metastasierten Nierenzellkarzinoms
ZusammenfassungIn den letzten 5 Jahren ist es zu einem Paradigmenwechsel in der Behandlung des metastasierten Nierenzellkarzinoms… 
Highly Cited
2008
Highly Cited
2008
Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study
9006 Background: No treatment has extended survival in stage IV melanoma. Melanomas are highly angiogenic and metastatic, express…